Chikungunya Vaccine

The manufacturing agreement is to provide Chikungunya Vaccine to low-and middle-income countries

People infected with the chikungunya virus continue to have an increased risk of death for up to three months post-infection, according to a study published in The Lancet Infectious Diseases journal. Chikungunya is a viral disease transmitted by mosquitoes to humans. Most commonly, the virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes, more commonly known as yellow fever and tiger mosquitoes, respectively. While most patients recover fully, chikungunya disease can prove fatal. Despite infections going largely unreported, approximately five lakh cases and over 400 deaths were recorded worldwide in 2023, the researchers said. "With chikungunya infections expected to increase, it's important that health services consider the risks that persist even after the acute phase of infection has ended," said Enny Da Paixao Cruz, Associate Professor at the London School of Hygiene & Tropical Medicine (LSHTM), UK, and senior author of the study. The researchers analysed ...

Symptoms of chikungunya can sometimes last for months or even years, but the virus is rarely fatal

The stock rose as much as 3.4 per cent in Paris trading

A single-dose vaccine for chikungunya was found safe and produced a strong immune response against the viral disease, according to the first phase 3 trial of the preventive published in The Lancet journal. However, the researchers were unable to investigate whether the VLA1553 vaccine, developed by French biotech company Valneva, protects against subsequent disease since the study was not conducted in regions where chikungunya is endemic. Chikungunya is a mosquito-borne disease caused by the chikungunya virus (CHIKV), which is endemic in some regions of Africa, Asia, and the Americas. It causes a fever in patients roughly four to eight days after they have been bitten by an infected mosquito. Symptoms include headaches, fatigue, nausea, and severe muscle and joint pain. The joint pain is often debilitating and usually lasts for a few days but may be prolonged, lasting for weeks, months or even years. Serious disease and death is rare, but older people and newborn babies are most a

Death from chikungunya is rare but it can cause severe health issues in some people. Here are more details about the illness, its symptoms, and prevention methods

The vaccine completed standard pre-clinical studies, and an optimum immune response was elicited by the adjuvant vaccine in phase-1 trials in India

Chikungunya is a dreaded infection transmitted through the bite of mosquito

BS ReporterHyderabad, 6 June: Hyderabad-based vaccine manufacturer Bharat Biotech announced today that the phase 1 of human clinical trials of the indigenously developed Chikungunya vaccine was underway in India to evaluate the vaccine's safety, tolerability and immunogenicity . The placebo controlled study involving 60 healthy volunteers would test escalating doses of the vaccine in prime-boost regimen, the company informed.Bharat Biotech developed the CHIKV vaccine using an isolate of the virus from Indian epidemic. The inactivated virus vaccine developed by the in-house R&D was found to be safe and immunogenic in pre-clinical animal testing, according to the company.After successful completion of product development and pre-clinical testing, the candidate vaccine was approved by the DCG(1) for phase 1 clinical trials in 2016."Chikungunya is one among the modern day's most dreaded virus, and developing an efficient vaccine to prevent it means a lot to people at risk for the ...